Person: TOPÇU, ATAKAN
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Is There a Relation Between Pretreatment CONUT Score and Neoadjuvant Chemotherapy Response in Breast Cancer Patients?(2022-06-01T00:00:00Z) YASİN, Ayşe İrem; TOPÇU, Atakan; YASİN, AYŞE İREM; TOPÇU, ATAKANObjective: To evaluate the relationship between pre-treatment nutritional status and pathological complete response (pCR) rates in patients with breast cancer.Publication Metadata only Impact of Malnutrition on Prognosis in Patients with HER2-negative Metastatic Gastric Cancer(2022-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; TOPÇU, ATAKAN; YASİN, AYŞE İREMObjective: Malnutrition is common in patients with gastric cancer and may adversely affect their prognosis. This study investigated the impact of malnutrition on overall survival (OS) in patients with metastatic gastric cancer by computing the Malnutrition Universal Screening Tool (MUST), one of the most used nutritional screening tools.Publication Metadata only Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study(2022-04-01T00:00:00Z) GÜRSOY, PINAR; TATLI, ALİ MURAT; Erdem, Dilek; GÖKER, ERDEM; Celik, Emir; Demirci, Nebi Serkan; Sakin, Abdullah; Atci, Muhammed Mustafa; Bayram, Ertugrul; AKIN TELLİ, TUĞBA; Bilgin, Burak; Bilici, Ahmet; Akangunduz, Baran; BALLI, SEVİNÇ; DEMİRKAZIK, AHMET; Selcukbiricik, Fatih; Menekse, Serkan; Cavdar, Eyyup; Ozturk, Akin; Bekmez, Esma Turkmen; Turhal, Serdal; Kilickap, Sadettin; YILDIRIM, HASAN ÇAĞRI; Oyan, Basak; AKSOY, ASUDE; Turkoz, Fatma Paksoy; Kut, Engin; Katgi, Nuran; Sakalar, Teoman; Akyol, Murat; ELLEZ, HALİL İBRAHİM; TOPÇU, Atakan; Erdogan, Atike Pinar; Pilanci, Kezban Nur; Hedem, Engin; Arak, Haci; Akdeniz, Nadiye; Alan, Ozkan; Yapar, Burcu; NART, DENİZ; Yumuk, Perran Fulden; TOPÇU, ATAKANObjectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.Publication Metadata only Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma(2022-06-01T00:00:00Z) Shbair, Abdallah T. M.; YASİN, Ayşe İrem; TOPÇU, Atakan; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİH; YASİN, AYŞE İREM; TOPÇU, ATAKAN; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİHBesides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.Publication Metadata only A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer(2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMETIntroduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.Publication Metadata only Relationship between KRAS mutation and diffusion tensor imaging features in brain metastases due to colorectal cancer; preliminary study(2021-05-01T00:00:00Z) Yılmaz, Temel Fatih; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; YILMAZ, TEMEL FATİH; TOPÇU, ATAKAN; ÇOBAN, GANİMEIdentifying Kirsten rat sarcoma (KRAS) mutation status is important for metastatic colorectal cancer treatment. Validating KRAS mutation profile on neuroimaging without histopathologic analysis would be beneficial. We aimed to differentiate Kirsten rat sarcoma (KRAS) gene mutation profile according to diffusion tensor imaging (DTI) metrics obtained from colorectal brain metastases (CRBM). Total of 8 patients with 17 CRBM included with known KRAS gene mutation status. All patients were categorized into two groups according to the KRAS mutation status as positive (+) (n: 5, 11 lesions) and negative (-) (wild type) (n: 3, 6 lesions). DTI values of the BMs were evaluated by consensus of two radiologists. Apparent diffusion coefficient (ADC), normalized apparent diffusion coefficient (nADC) and fractional anisotropy (FA) values of the two groups were compared. For comparison the Mann-Whitney U test was used. KRAS mutation (+) group showed significantly lower ADC and nADC values on CRBM rather than the wild-type. Comparison of the FA values of the two groups did not reveal any statistical significance. In conclusion, decreased ADC and nADC values of CRBM are correlated with presence of KRAS mutation. Lower ADC and nADC values obtained from CRBM can be utilized to insight KRAS mutation profile.Publication Metadata only Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer(2022-01-01) Goktas Aydin S.; Cakan Demirel B.; Bilici A.; TOPÇU A.; Aykan M. B.; KAHRAMAN S.; AKBIYIK I.; Atci M. M.; Olmez O. F.; Yaren A.; et al.; TOPÇU, ATAKAN; ŞEKER, MESUT© 2022 Informa UK Limited, trading as Taylor & Francis Group.Objectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to investigate the role of systemic inflammatory parameters (SIP) and other possible independent factors that may affect survival and treatment approaches and to determine the benefit of later-line treatments in these patients. Methods: A total of 284 patients, initially diagnosed with advanced stage or progressed after curative treatment of BTC, from different oncology centers in Turkey were included in this retrospective study. The prognostic significance of clinicopathological factors, SIPs and treatment options was analyzed. Results: At a median follow-up of 13 months, the median progression-free survival (PFS) was 6.1 months (95% CI:5.51–6.82), and the median overall survival (OS) time was 16.8 months (95% CI: 13.9–19.6). Treatment choice (p <.001 HR:0.70 CI95% 0.55–0.9), performance status (p <.001 HR:2.74 CI 95% 2.12–3.54) and neutrophil-to-lymphocyte ratio (NLR) (p =.02 HR:1.38 CI 95% 1.03–1.84) were independent prognostic factors for PFS. For OS, the independent prognostic indicators were determined as The Eastern Cooperative Oncology Group Performance Status (ECOG PS) (p <.001 HR:1.78 CI 95% 1.5–2.3), Systemic Immune-inflammation Index (SII) (p <.001 HR:0.51 CI95% 0.36–0.73) and stage at diagnosis (p =.002 HR:1.79 CI 95% 1.24–2.59). Furthermore, second and third line treatments significantly prolonged OS in advanced BTC (p <.001 HR:0.55 CI 95% 0.38–0.79; p =.007 HR:0.51 CI95% 0.31–0.83, respectively). Conclusion: SII and NLR are useful prognostic factors and may be helpful in making treatment decisions. Additionally, second and later-line treatments in advanced BTC have a significant impact on survival under real-life conditions.